ALT5 Sigma (NASDAQ:ALTS) Shares Down 2.2% – What’s Next?

ALT5 Sigma Corporation (NASDAQ:ALTS)’s share price traded down 2.2% during trading on Thursday . The company traded as low as $1.29 and last traded at $1.32. 1,152,010 shares traded hands during trading, a decline of 43% from the average session volume of 2,021,641 shares. The stock had previously closed at $1.35.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of ALT5 Sigma in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

ALT5 Sigma Price Performance

The company has a debt-to-equity ratio of 0.01, a current ratio of 0.79 and a quick ratio of 0.79. The stock has a 50-day simple moving average of $1.66 and a 200-day simple moving average of $2.01.

ALT5 Sigma (NASDAQ:ALTS) last issued its quarterly earnings results on Monday, January 12th. The company reported $0.29 EPS for the quarter. The firm had revenue of $7.58 million for the quarter. ALT5 Sigma had a return on equity of 8.60% and a net margin of 133.06%.

Institutional Investors Weigh In On ALT5 Sigma

Several institutional investors have recently added to or reduced their stakes in the business. Balyasny Asset Management L.P. purchased a new position in shares of ALT5 Sigma in the fourth quarter worth about $26,000. Arete Wealth Advisors LLC purchased a new stake in shares of ALT5 Sigma during the 3rd quarter valued at approximately $28,000. Profund Advisors LLC bought a new position in ALT5 Sigma in the 3rd quarter worth approximately $28,000. Victory Capital Management Inc. bought a new position in ALT5 Sigma in the 3rd quarter worth approximately $33,000. Finally, First Citizens Bank & Trust Co. purchased a new position in ALT5 Sigma in the 3rd quarter valued at approximately $35,000. 6.27% of the stock is owned by hedge funds and other institutional investors.

ALT5 Sigma Company Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.